Hepatitis B

http://www.cdc.gov/nip/publications/pink/hepb.pdf

Both the pediatric and adult formulations of Recombivax HB are approved for use in any age group. For example, the adult formulation of Recombivax HB may be used in children
(0.5 mL) and adolescents (0.5 mL). However, pediatric Engerix-B is approved for use only in children and adolescents younger than 20 years of age. The adult formulation of Engerix-B is not approved for use in infants and children but may be used in both adolescents (11–19 years of age) and adults.
Engerix-B contains aluminum hydroxide as an adjuvant.
It does not contain thimerosal as a preservative but contains a trace of thimerosal as residual from the manufacturing process. The vaccine is supplied in singledose vials and syringes. recombivax HB contains aluminum hydroxyphosphate sulfate as an adjuvant. None of the formulations of Recombivax HB contain thimerosal or any other preservative. The vaccine is supplied in single
dose vials.

Hepatitis B vaccine has been alleged to cause or exacerbate
multiple sclerosis (MS). A 2004 retrospective study in a British population found a slight increase in risk of MS among hepatitis B vaccine recipients. However, large population-based studies have shown no association between receipt of hepatitis B vaccine and either the development of MS or exacerbation of the course of MS is persons already diagnosed with the disease.